Renaissance Technologies LLC raised its stake in Chiasma Inc (NASDAQ:CHMA) by 20.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,700 shares of the biotechnology company’s stock after buying an additional 14,300 shares during the quarter. Renaissance Technologies LLC owned approximately 0.34% of Chiasma worth $298,000 at the end of the most recent quarter.

Separately, Citadel Advisors LLC grew its holdings in Chiasma by 100.6% in the 3rd quarter. Citadel Advisors LLC now owns 35,656 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 17,881 shares in the last quarter. 61.02% of the stock is currently owned by institutional investors.

A number of equities analysts have recently weighed in on CHMA shares. Brookline Capital Management reiterated a “buy” rating on shares of Chiasma in a report on Wednesday. ValuEngine cut Chiasma from a “buy” rating to a “hold” rating in a report on Friday, January 4th.

NASDAQ CHMA opened at $3.40 on Friday. The firm has a market cap of $85.51 million, a PE ratio of -3.21 and a beta of 1.37. Chiasma Inc has a twelve month low of $1.20 and a twelve month high of $4.87.

Chiasma (NASDAQ:CHMA) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.31) earnings per share for the quarter. As a group, research analysts predict that Chiasma Inc will post -1.28 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Featured Story: Why is Cost of Capital Important?

Want to see what other hedge funds are holding CHMA? Visit to get the latest 13F filings and insider trades for Chiasma Inc (NASDAQ:CHMA).

Institutional Ownership by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with's FREE daily email newsletter.